Ayala Pharmaceuticals Inc (ADXS)

[mpreorder]

Blue -It's hard, or impossible actually, for me to disagree with anything you said.
- HER2 wasn't very developed
- HER2 was going to be a major cash burn
- Advaxis can't afford another cash burn without dilution or income which isn't on the horizon

However, the sentence in the PR speaks for itself. They said they looked at the data, looked at the companies priorities, then killed the trial.

If the data supported further investigation, why include the fact that they looked at the data? Why not just say "because of company priorities...." or something similar? To me they were sending a signal. And IF they WERE sending a signal then HER2 is going to be VERY difficult to sell.

Again, I hope you ARE correct, and we can and do license this construct. Time will tell.